Cellceutix

Thank You - Seite 3

The maligned attack on the credentials of Dr. Menon and others associated with Cellceutix that seems to emerge as part of short campaigns is without merit. Dr. Menon is an incredible and well-respected scientist. Let me state some facts. Fact: Eli Lilly honored Dr. Menon with the prestigious President's Recognition Award (http://cellceutix.com/presidents-recognition-award/#sthash.2HCoVlCH.ptVZnKIC.dpbs). This is an award given very seldom to employees of Lilly, a corporation of tens of thousands of employees. The award was given because of Dr. Menon's excellence in lab research and discoveries that helped Lilly expand the potential of several cancer drugs. There was an administrative error stating that Dr. Menon earned his PhD from Harvard, when the fact is that Dr. Menon worked as a research scientist at Dana-Farber Cancer Institute. This error was corrected years ago. The article that was published by India New England years ago was simply absurd and was removed by the publisher with all its links as an admission that the story was false.

Fact: Dr. Emil Frei, a legend in the world of oncology, and Dr. Har Gobind Khorana, a Nobel Prize winner, were founders of CTIX and appear on the original transfer agent stockholder report of the Company.

Others laudable for their work in the growth of Cellceutix that were maliciously disparaged in the recent article include Dr. Sylvia Holden, an amazing researcher at Cellceutix, and Dr. Paul Ginsberg, a renowned patent attorney who was integral to Cellceutix's patents for Kevetrin and Prurisol. The author uses Google images to post pictures of these peoples' homes which incidentally are of high value, as a means of somehow trying to lend credence to the preposterous concepts that Dr. Holden and Dr. Ginsberg have no value to Cellceutix. The following are links to the Cellceutix patents that Dr. Ginsberg helped write: Kevetrin: http://www.google.com/patents/US8338454
Prurisol: http://www.google.com/patents/WO2013103601A1?cl=en

If one takes a moment to analyze our growth since we began to work with Aspire Capital in December 2012, when shares of CTIX were around $1.20 each, it is easy to see how their investment has provided us with the resources to grow our company and build shareholder value. In three years, shares are still ahead from that point, in spite of numerous, less-than-credible attacks on the Cellceutix in recent years, including this last one. See Chart